Impairments of hepatic gluconeogenesis and ketogenesis in PPARα-deficient neonatal mice

American Journal of Physiology - Endocrinology and Metabolism

Volumn 307, Issue 2, 2014, Pages

  Cotter, David G ^a,b   Ercal, Baris ^a   Andre D'Avignon D ^c   Dietzen, Dennis J ^b   Crawford, Peter A ^a,d  

^a Center for Cardiovascular Research   (United States)

^b Department of Pediatrics   (United States)

^c Departments of Chemistry   (United States)

^d WASHINGTON UNIVERSITY   (United States)

Author keywords

3 hydroxymethylglutaryl CoA synthase; Glucose homeostasis; Ketone body metabolism; Metabolic adaptation to birth; Nuclear magnetic resonance substrate fate mapping; Peroxisome proliferator activated receptor a

Indexed keywords

3-HYDROXYMETHYLGLUTARYL-COA SYNTHASE; GLUCOSE HOMEOSTASIS; KETONE BODY METABOLISM; METABOLIC ADAPTATION TO BIRTH; NUCLEAR MAGNETIC RESONANCE SUBSTRATE FATE MAPPING; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-Α;

ANIMALS; ANIMALS, NEWBORN; FATTY ACIDS; GLUCONEOGENESIS; GLYCEROL; HYPOGLYCEMIA; KETONE BODIES; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXIDATION-REDUCTION; PPAR ALPHA;

EID: 84904307658     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00087.2014     Document Type: Article

References (49)

1. Abdelmegeed MA, Yoo SH, Henderson LE, Gonzalez FJ, Woodcroft KJ, Song BJ. PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver. J Nutr 141: 603-610, 2011.
2. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 10: 330-344, 2013.
3. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5: 426-437, 2007.
4. Befroy DE, Perry RJ, Jain N, Dufour S, Cline GW, Trimmer JK, Brosnan J, Rothman DL, Petersen KF, Shulman GI. Direct assessment of hepatic mitochondrial oxidative and anaplerotic fluxes in humans using dynamic (13)C magnetic resonance spectroscopy. Nat Med 20: 98-102, 2014.
5. Burgess SC, He T, Yan Z, Lindner J, Sherry AD, Malloy CR, Browning JD, Magnuson MA. Cytosolic phosphoenolpyruvate carboxykinase does not solely control the rate of hepatic gluconeogenesis in the intact mouse liver. Cell Metab 5: 313-320, 2007.
6. Cahill GF Jr. Fuel metabolism in starvation. Annu Rev Nutr 26: 1-22, 2006.
7. Chakravarthy MV, Lodhi IJ, Yin L, Malapaka RR, Xu HE, Turk J, Semenkovich CF. Identification of a physiologically relevant endogenous ligand for PPARalpha in liver. Cell 138: 476-488, 2009.
8. Chakravarthy MV, Pan Z, Zhu Y, Tordjman K, Schneider JG, Coleman T, Turk J, Semenkovich CF. "New" hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cell Metab 1: 309-322, 2005.
9. Cotter DG, d'Avignon DA, Wentz AE, Weber ML, Crawford PA. Obligate role for ketone body oxidation in neonatal metabolic homeostasis. J Biol Chem 286: 6902-6910, 2011.
10. Cotter DG, Ercal B, d'Avignon DA, Dietzen DJ, Crawford PA. Impact of peripheral ketolytic deficiency on hepatic ketogenesis and gluconeogenesis during the transition to birth. J Biol Chem 288: 19739-19749, 2013.
11. Cotter DG, Schugar RC, Crawford PA. Ketone body metabolism and cardiovascular disease. Am J Physiol Heart Circ Physiol 304: H1060-H1076, 2013.
12. Cotter DG, Schugar RC, Wentz AE, d'Avignon DA, Crawford PA. Successful adaptation to ketosis by mice with tissue-specific deficiency of ketone body oxidation. Am J Physiol Endocrinol Metab 304: E363-E374, 2013.
13. Crawford PA, Crowley JR, Sambandam N, Muegge BD, Costello EK, Hamady M, Knight R, Gordon JI. Regulation of myocardial ketone body metabolism by the gut microbiota during nutrient deprivation. Proc Natl Acad Sci USA 106: 11276-11281, 2009.
14. Dean JT, Tran L, Beaven S, Tontonoz P, Reue K, Dipple KM, Liao JC. Resistance to diet-induced obesity in mice with synthetic glyoxylate shunt. Cell Metab 9: 525-536, 2009.
15. Dietzen DJ, Weindel AL, Carayannopoulos MO, Landt M, Normansell ET, Reimschisel TE, Smith CH. Rapid comprehensive amino acid analysis by liquid chromatography/tandem mass spectrometry: comparison to cation exchange with post-column ninhydrin detection. Rapid Commun Mass Spectrom 22: 3481-3488, 2008.
16. Fabbrini E, Mohammed BS, Korenblat KM, Magkos F, McCrea J, Patterson BW, Klein S. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 95: 2727-2735, 2010.
17. Fernández-Miranda C, Pérez-Carreras M, Colina F, López-Alonso G, Vargas C, Solís-Herruzo JA. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 40: 200-205, 2008.
18. Gélinas R, Labarthe F, Bouchard B, Mc Duff J, Charron G, Young ME, Des Rosiers C. Alterations in carbohydrate metabolism and its regulation in PPARα null mouse hearts. Am J Physiol Heart Circ Physiol 294: H1571-H1580, 2008.
19. Girard J, Ferré P, Pégorier JP, Duée PH. Adaptations of glucose and fatty acid metabolism during perinatal period and suckling-weaning transition. Physiol Rev 72: 507-562, 1992.
20. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, Li Y, Goetz R, Mohammadi M, Esser V, Elmquist JK, Gerard RD, Burgess SC, Hammer RE, Mangelsdorf DJ, Kliewer SA. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 5: 415-425, 2007.
21. Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 38: 123-132, 2003.
22. Jones JG, Hansen J, Sherry AD, Malloy CR, Victor RG. Determination of acetyl-CoA enrichment in rat heart and skeletal muscle by 1H nuclear magnetic resonance analysis of glutamate in tissue extracts. Anal Biochem 249: 201-206, 1997.
23. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 103: 1489-1498, 1999.
24. Leone TC, Weinheimer CJ, Kelly DP. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: The PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA 96: 7473-7478, 1999.
25. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10: 686-690, 2013.
26. Magnusson I, Schumann WC, Bartsch GE, Chandramouli V, Kumaran K, Wahren J, Landau BR. Noninvasive tracing of Krebs cycle metabolism in liver. J Biol Chem 266: 6975-6984, 1991.
27. Makowski L, Noland RC, Koves TR, Xing W, Ilkayeva OR, Muehlbauer MJ, Stevens RD, Muoio DM. Metabolic profiling of PPARalpha / mice reveals defects in carnitine and amino acid homeostasis that are partially reversed by oral carnitine supplementation. FASEB J 23: 586-604, 2009.
28. Mandard S, Muller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci 61: 393-416, 2004.
29. Mannaerts GP, Thomas J, Debeer LJ, McGarry JD, Foster DW. Hepatic fatty acid oxidation and ketogenesis after clofibrate treatment. Biochim Biophys Acta 529: 201-211, 1978.
30. McGarry JD, Foster DW. Regulation of hepatic fatty acid oxidation and ketone body production. Annu Rev Biochem 49: 395-420, 1980.
31. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 10: 656-665, 2013.
32. Oosterveer MH, Grefhorst A, van Dijk TH, Havinga R, Staels B, Kuipers F, Groen AK, Reijngoud DJ. Fenofibrate simultaneously induces hepatic fatty acid oxidation, synthesis, and elongation in mice. J Biol Chem 284: 34036-34044, 2009.
33. Orii KE, Fukao T, Song XQ, Mitchell GA, Kondo N. Liver-specific silencing of the human gene encoding succinyl-CoA: 3-ketoacid CoA transferase. Tohoku J Exp Med 215: 227-236, 2008.
34. Patsouris D, Mandard S, Voshol PJ, Escher P, Tan NS, Havekes LM, Koenig W, März W, Tafuri S, Wahli W, Müller M, Kersten S. PPARalpha governs glycerol metabolism. J Clin Invest 114: 94-103, 2004.
35. Rakhshandehroo M, Sanderson LM, Matilainen M, Stienstra R, Carlberg C, de Groot PJ, Müller M, Kersten S. Comprehensive analysis of PPARalpha-dependent regulation of hepatic lipid metabolism by expression profiling. PPAR Res 2007: 26839, 2007.
36. Rardin MJ, He W, Nishida Y, Newman JC, Carrico C, Danielson SR, Guo A, Gut P, Sahu AK, Li B, Uppala R, Fitch M, Riiff T, Zhu L, Zhou J, Mulhern D, Stevens RD, Ilkayeva OR, Newgard CB, Jacobson MP, Hellerstein M, Goetzman ES, Gibson BW, Verdin E. SIRT5 regulates the mitochondrial lysine succinylome and metabolic networks. Cell Metab 18: 920-933, 2013.
37. Ratziu V. Pharmacological agents for NASH. Nat Rev Gastroenterol Hepatol 10: 676-685, 2013.
38. Robinson AM, Williamson DH. Physiological roles of ketone bodies as substrates and signals in mammalian tissues. Physiol Rev 60: 143-187, 1980.
39. Rodriguez JC, Gil-Gomez G, Hegardt FG, Haro D. Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids. J Biol Chem 269: 18767-18772, 1994.
40. Satapati S, He T, Inagaki T, Potthoff M, Merritt ME, Esser V, Mangelsdorf DJ, Kliewer SA, Browning JD, Burgess SC. Partial resistance to peroxisome proliferator-activated receptor-alpha agonists in ZDF rats is associated with defective hepatic mitochondrial metabolism. Diabetes 57: 2012-2021, 2008.
41. Shimazu T, Hirschey MD, Hua L, Dittenhafer-Reed KE, Schwer B, Lombard DB, Li Y, Bunkenborg J, Alt FW, Denu JM, Jacobson MP, Verdin E. SIRT3 deacetylates mitochondrial 3-hydroxy-3-methylglutaryl CoA synthase 2 and regulates ketone body production. Cell Metab 12: 654-661, 2010.
42. Shiri-Sverdlov R, Wouters K, van Gorp PJ, Gijbels MJ, Noel B, Buffat L, Staels B, Maeda N, van Bilsen M, Hofker MH. Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. J Hepatol 44: 732-741, 2006.
43. Tremblay-Mercier J, Tessier D, Plourde M, Fortier M, Lorrain D, Cunnane SC. Bezafibrate mildly stimulates ketogenesis and fatty acid metabolism in hypertriglyceridemic subjects. J Pharmacol Exp Ther 334: 341-346, 2010.
44. Ward Platt M, Deshpande S. Metabolic adaptation at birth. Semin Fetal Neonatal Med 10: 341-350, 2005.
45. Wentz AE, d'Avignon DA, Weber ML, Cotter DG, Doherty JM, Kerns R, Nagarajan R, Sambandam N, Crawford PA. Adaptation of myocardial substrate metabolism to a ketogenic nutrient environment. J Biol Chem 285: 24447-24456, 2010.
46. Williamson DH, Bates MW, Page MA, Krebs HA. Activities of enzymes involved in acetoacetate utilization in adult mammalian tissues. Biochem J 121: 41-47, 1971.
47. Williamson JR, Browning ET, Scholz R. Interactions between fatty acid oxidation and the citric acid cycle in perfused rat liver. J Biol Chem 244: 4617-4627, 1969.
48. Xu J, Xiao G, Trujillo C, Chang V, Blanco L, Joseph SB, Bassilian S, Saad MF, Tontonoz P, Lee WN, Kurland IJ. Peroxisome proliferatoractivated receptor alpha (PPARalpha) influences substrate utilization for hepatic glucose production. J Biol Chem 277: 50237-50244, 2002.
49. Yamamoto K, Fukuda N, Zhang L, Sakai T. Altered hepatic metabolism of fatty acids in rats fed a hypolipidaemic drug, fenofibrate. Pharmacol Res 33: 337-342, 1996.